Prinaberel
Prinaberel (also known as ERB-041) is a synthetic, orally active and selective estrogen receptor beta (ERβ) agonist which was under development by Wyeth but was ultimately discontinued. It was being investigated for the treatment of rheumatoid arthritis and inflammatory bowel disease and had completed Phase II clinical trials for these indications.
Pharmacology[edit | edit source]
Prinaberel selectively binds to and activates ERβ, one of two main types of estrogen receptor. The activation of ERβ has anti-inflammatory effects and can be beneficial in the treatment of conditions like rheumatoid arthritis and inflammatory bowel disease.
Clinical trials[edit | edit source]
Prinaberel has completed Phase II clinical trials for the treatment of rheumatoid arthritis and inflammatory bowel disease. However, the development of the drug was discontinued by Wyeth.
See also[edit | edit source]
- Estrogen receptor beta
- Wyeth
- Rheumatoid arthritis
- Inflammatory bowel disease
- Phase II clinical trials
References[edit | edit source]
Prinaberel Resources | ||
---|---|---|
|
|
Translate to: East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD